LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Heron Therapeutics Inc

Heron Therapeutics Inc

Closed

Sector Healthcare

1.79

Buy Sell

Overview

Share price change

24h

Current

Min

1.78

Max

1.8

Key metrics
By Trading Economics
Income	-25M
Sales	2.8M 34M
EPS	-0.07
Profit margin	-79.557
Employees	126
EBITDA	-24M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+233.33 upside

Market Stats
By TradingEconomics
Market Cap	1.5M 421M
Previous open	1.79
Previous close	1.79

News Sentiment

By Acuity

50%

114 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

1.799 / 1.93 Support & Resistance

Heron Therapeutics Inc Chart

Related News

24 Jan 2024, 15:35 UTC

Major Market Movers

Heron Therapeutics Shares Rise 15% After FDA Approves Expanded Use of Zynrelef

Peer Comparison

Price change

Heron Therapeutics Inc Forecast

Price Target

By TipRanks

233.33% upside

12 Months Forecast

Average 6 USD 233.33%

High 7 USD

Low 5 USD

Based on 2 Wall Street analysts offering 12 month price targets forHeron Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Heron Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.799 / 1.93Support & Resistance

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

114 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Heron Therapeutics Inc

Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.